JP2018517704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517704A5 JP2018517704A5 JP2017562664A JP2017562664A JP2018517704A5 JP 2018517704 A5 JP2018517704 A5 JP 2018517704A5 JP 2017562664 A JP2017562664 A JP 2017562664A JP 2017562664 A JP2017562664 A JP 2017562664A JP 2018517704 A5 JP2018517704 A5 JP 2018517704A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- composition
- mir
- nucleotide
- oligonucleotide inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 59
- 239000003112 inhibitor Substances 0.000 claims description 59
- 239000002773 nucleotide Substances 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 108091033773 MiR-155 Proteins 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 108020004414 DNA Proteins 0.000 claims description 15
- 102000053602 DNA Human genes 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 15
- 210000003169 central nervous system Anatomy 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 125000001921 locked nucleotide group Chemical group 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 10
- 210000004969 inflammatory cell Anatomy 0.000 claims description 10
- 208000025966 Neurological disease Diseases 0.000 claims description 9
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 210000000274 microglia Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 230000007115 recruitment Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 5
- 230000013632 homeostatic process Effects 0.000 description 4
- 230000002669 organ and tissue protective effect Effects 0.000 description 2
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 1
- 101150053778 CSF1R gene Proteins 0.000 description 1
- 101150059254 Cux1 gene Proteins 0.000 description 1
- 101150050733 Gnas gene Proteins 0.000 description 1
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 101150080778 INPP5D gene Proteins 0.000 description 1
- 101150022636 MAFB gene Proteins 0.000 description 1
- 101150083522 MECP2 gene Proteins 0.000 description 1
- 101150082764 MR1 gene Proteins 0.000 description 1
- 101100298093 Mus musculus Pnkd gene Proteins 0.000 description 1
- 101100189144 Mus musculus Serpine1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150116584 Rapgef5 gene Proteins 0.000 description 1
- 101150093886 TGFBR2 gene Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 101150034865 mef2a gene Proteins 0.000 description 1
- 101150013771 olfml3 gene Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562171743P | 2015-06-05 | 2015-06-05 | |
| US62/171,743 | 2015-06-05 | ||
| PCT/US2016/035794 WO2016196978A1 (en) | 2015-06-05 | 2016-06-03 | Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018517704A JP2018517704A (ja) | 2018-07-05 |
| JP2018517704A5 true JP2018517704A5 (enExample) | 2019-07-04 |
Family
ID=57442041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562664A Pending JP2018517704A (ja) | 2015-06-05 | 2016-06-03 | 筋萎縮性側索硬化症（ＡＬＳ）を処置するためのｍｉＲ−１５５阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180161357A1 (enExample) |
| EP (1) | EP3303589A4 (enExample) |
| JP (1) | JP2018517704A (enExample) |
| CN (1) | CN107922947A (enExample) |
| CA (1) | CA2986913A1 (enExample) |
| WO (1) | WO2016196978A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140074997A (ko) | 2011-10-11 | 2014-06-18 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 신경병성 질환에서 마이크로rna |
| KR20190118688A (ko) | 2015-06-05 | 2019-10-18 | 미라젠 세러퓨틱스 인코포레이티드 | 피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제 |
| US11957713B2 (en) | 2016-10-14 | 2024-04-16 | Children's Medical Center Corporation | Compositions and methods for treating diseases and disorders of the central nervous system |
| CA3050690A1 (en) | 2017-01-17 | 2018-07-26 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for diagnosing and treating peroxisomal diseases |
| WO2018136435A1 (en) | 2017-01-17 | 2018-07-26 | Children's Medical Center Corporation | Compositions and methods for treating lysosomal storage diseases and disorders |
| WO2019195304A1 (en) | 2018-04-03 | 2019-10-10 | Academia Sinica | Mir-17~92 as therapeutic or diagnostic target of motor neuron (mn) degeneration diseases |
| CN112585280A (zh) | 2018-08-23 | 2021-03-30 | 罗氏创新中心哥本哈根有限公司 | 微小rna-134生物标志物 |
| WO2021067613A1 (en) * | 2019-10-01 | 2021-04-08 | Children's Medical Center Corporation | Compositions and methods for treating amyotrophic lateral sclerosis |
| CN114272378B (zh) * | 2020-09-27 | 2023-06-23 | 四川大学华西医院 | 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途 |
| CN112587662A (zh) * | 2020-12-22 | 2021-04-02 | 上海市徐汇区中心医院 | 一种miR-155/PEA15信号通路抑制剂在病理性心脏重构药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101437942A (zh) * | 2006-04-03 | 2009-05-20 | 桑塔里斯制药公司 | 包含抗微小rna反义寡核苷酸的药物组合物 |
| CA3024953A1 (en) * | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| PL2623598T3 (pl) * | 2007-10-04 | 2018-12-31 | Roche Innovation Center Copenhagen A/S | Micromir |
| EP2268811A1 (en) * | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| ES2581178T3 (es) * | 2009-07-29 | 2016-09-01 | Pharnext | Nuevas herramientas de diagnóstico para enfermedad de Alzheimer |
| KR20140074997A (ko) * | 2011-10-11 | 2014-06-18 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 신경병성 질환에서 마이크로rna |
| WO2013134403A1 (en) * | 2012-03-06 | 2013-09-12 | The Washington University | Method of treating neurodegenerative diseases with microrna regulators |
-
2016
- 2016-06-03 CA CA2986913A patent/CA2986913A1/en not_active Abandoned
- 2016-06-03 US US15/579,718 patent/US20180161357A1/en not_active Abandoned
- 2016-06-03 EP EP16804549.0A patent/EP3303589A4/en not_active Withdrawn
- 2016-06-03 JP JP2017562664A patent/JP2018517704A/ja active Pending
- 2016-06-03 WO PCT/US2016/035794 patent/WO2016196978A1/en not_active Ceased
- 2016-06-03 CN CN201680038698.3A patent/CN107922947A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517704A5 (enExample) | ||
| Crow et al. | Targeting of type I interferon in systemic autoimmune diseases | |
| US20190062740A1 (en) | COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS | |
| JP2017505623A5 (enExample) | ||
| EP2766482A1 (en) | Micrornas in neurodegenerative disorders | |
| JP2016502858A5 (enExample) | ||
| JP6855480B2 (ja) | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 | |
| JP2016522674A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| US20250136984A1 (en) | Oligonucleotide agonists targeting progranulin | |
| JP2015523854A5 (enExample) | ||
| JP2017519766A5 (enExample) | ||
| JP2017532961A5 (enExample) | ||
| JP2015518713A5 (enExample) | ||
| JP2018519835A5 (enExample) | ||
| WO2017192662A2 (en) | Methods for identifying treatment targets based on multiomics data | |
| JP2021500016A5 (enExample) | ||
| Saeed | Lupus pathobiology based on genomics | |
| JP2013507127A5 (enExample) | ||
| US20200407721A1 (en) | Compounds of chemically modified oligonucleotides and methods of use thereof | |
| JP2019523302A5 (enExample) | ||
| WO2019199733A1 (en) | Compositions and methods for treating cancer | |
| JP7576835B2 (ja) | 自己免疫疾患および癌を治療するための可溶性インターロイキン７受容体（ｓＩＬ７Ｒ）調節療法 | |
| JP6049143B2 (ja) | オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター | |
| Sanchez et al. | Characterization of frataxin gene network in Friedreich's ataxia fibroblasts using the RNA-Seq technique |